Payment overview · 2025
General Payments
$2,172.12
134 reported records · 19 companies
Healthcare provider profile · identity verified
Brandon Trumble, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SPRINGFIELD, MO · NPI 1972932853
Verified facts
What the public records show
CMS Open Payments records show Brandon Trumble, FNP received $2,172.12 in general payments during 2025 across 134 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Rexulti, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $340.57 | 15.7% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $314.90 | 14.5% | 24 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $304.10 | 14.0% | 13 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $231.27 | 10.7% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $172.19 | 7.9% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $158.99 | 7.3% | 10 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $152.46 | 7.0% | 10 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $149.50 | 6.9% | 16 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $97.82 | 4.5% | 5 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $38.36 | 1.8% | 2 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $37.64 | 1.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.79 | 1.5% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.55 | 1.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.84 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.60 | 0.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.71 | 0.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.45 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.40 | 0.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.98 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,172.12 | 134 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $340.57 | 19 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $304.10 | 13 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $231.27 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $183.09 | 14 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $158.99 | 10 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $119.68 | 9 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $119.46 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $103.75 | 7 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $97.82 | 5 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $85.89 | 6 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $82.85 | 4 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $78.82 | 5 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $73.64 | 5 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $38.36 | 2 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $37.64 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.79 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.79 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $32.55 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $29.82 | 7 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $12.35 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $12.35 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 264 | 47 |
| Gabapentin | Gabapentin | 238 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 180 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 17 |
| Lisinopril | Lisinopril | 131 | 31 |
| Trazodone Hcl | Trazodone Hcl | 126 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 107 | 22 |
| Metformin Hcl | Metformin Hcl | 106 | 21 |
| Omeprazole | Omeprazole | 102 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 19 |
| Buprenorphine Hcl | Buprenorphine Hcl | 93 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 87 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 85 | 21 |
| Celecoxib | Celecoxib | 75 | 18 |
| Baclofen | Baclofen | 74 | 17 |
| Pregabalin | Pregabalin | 72 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 13 |
| Tramadol Hcl | Tramadol Hcl | 56 | 13 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Ibuprofen | Ibuprofen | 55 | 12 |
| Losartan Potassium | Losartan Potassium | 55 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 55 | suppressed |
| Ondansetron Odt | Ondansetron | 54 | 22 |
| Olanzapine | Olanzapine | 53 | suppressed |
| Potassium Chloride | Potassium Chloride | 46 | suppressed |
| Meloxicam | Meloxicam | 45 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Furosemide | Furosemide | 43 | 12 |
| Prednisone | Prednisone | 43 | 23 |
| Bupropion Xl | Bupropion Hcl | 42 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 41 | suppressed |
| Topiramate | Topiramate | 41 | 11 |
| Alprazolam | Alprazolam | 37 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 35 | 32 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Loxapine | Loxapine Succinate | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Vraylar | Cariprazine Hcl | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 15 |
| Cephalexin | Cephalexin | 25 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 23 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Paliperidone Er | Paliperidone | 20 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 11 |
| Jardiance | Empagliflozin | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Micardis | Telmisartan | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,172.12 · 134 records | E.R. Squibb & Sons, L.L.C. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, APRETUDE, AUSTEDO XR, BRIXADI, Belbuca, CAPLYTA, COBENFY, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, JARDIANCE, JOURNAVX, MAVYRET, NURTEC ODT, QULIPTA, REXULTI, ROXYBOND, TRINTELLIX, UBRELVY, UZEDY, VRAYLAR, XTAMPZA, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error